KentCShihMD

Oncology • Nashville, TN

Hematologic Oncology, Neuro-Oncology

Physician

Join to view full profile

Dr. Shih is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shih's full profile

Already have an account?

Office
4220 Harding Pike
SE Building Suite 200
Nashville, TN 37205
Phone+1 615-385-3751

Fax+1 615-269-7085

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
Vanderbilt University Medical CenterResidency, Internal Medicine, 1997 - 2000
Vanderbilt University School of MedicineClass of 1997

Certifications & Licensure

TN State Medical License 1998 - 2026
LA State Medical License 2003 - 2007
MD State Medical License 2000 - 2003

Clinical Trials

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma Start of enrollment: 2011 Oct 01
Completed
Phase 1, Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Start of enrollment: 2014 May 01
Completed
Phase 1, Phase 2
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma Start of enrollment: 2014 Jul 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

27 citations
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
Sandra P. D'Angelo, Shailender Bhatia, A.S. Brohl, Omid Hamid, Janice M. Mehnert
ESMO Open. 2021-10-26
129 citations
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert
Journal for Immunotherapy of Cancer. 2020-05-01
27 citations
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squam...
David R. Spigel, Dianna Shipley, David M. Waterhouse, Suzanne F. Jones, Patrick J. Ward
The Oncologist. 2019-12-01

Journal Articles

Randomized Phase II Study of Akt Blockade with or Without Ipatasertib in Abiraterone-Treated Patients with Metastatic Prostate Cancer with and Without PTEN Loss
Kent Shih, MD, Clinical Cancer Research
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Kent C Shih, Kyriakos P Papadopoulos, Drew W Rasco, Clinical Cancer Research

Lectures

Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Brain Tumor Survivor Celebrates Birthday Virtually with Doctors Who Saved His LifeMarch 22nd, 2021
BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyNovember 16th, 2018